top of page

Gene-Edited Crops: How the EU's 2026 NGT Law Opens a USD 8.13 Billion Market

Writer: Strategic Revenue Insights
Strategic Revenue Insights
Nov 13
13 min read
Gene-edited crops: how the EU's 2026 NGT law opens a USD 8.13 billion market, Strategic Revenue Insights

Executive summary. For two decades, plant biotechnology was defined by a single regulatory fault line: a crop was either conventional or it was a genetically modified organism, with all the cost, delay and public resistance that the second label carried. Gene editing has broken that binary. Strategic Revenue Insights values the global gene-edited crops market at USD 2.10 billion in 2025 and forecasts USD 8.13 billion by 2035, a 14.5 percent compound annual growth rate and a 3.9x expansion in a decade. The catalyst is regulatory: the United States exempts many edited plants from biotechnology permitting, and in 2026 the European Union adopted a law that treats the simplest edited plants like conventionally bred ones. This article sets out five lessons from the seed companies, start-ups and research institutes moving first, with takeaways for strategy, research and development, regulatory affairs, go-to-market and revenue.


Regulation shapes this market more than any laboratory breakthrough. Strategic Revenue Insights' Gene-Edited Crops Market research finds that CRISPR-Cas holds 71.00 percent of 2025 revenue while base and prime editing is the fastest growing technique at 20.6 percent a year, that cereals and grains are the largest crop group at 39.00 percent, and that yield improvement is the largest trait at 28.00 percent while climate resilience grows fastest at 17.3 percent. Seed companies are the main buyers with 58.00 percent of revenue, farmers and growers hold 22.00 percent and grow fastest at 15.7 percent, and research institutes hold 20.00 percent. North America holds 36.00 percent of 2025 revenue and Asia Pacific 34.00 percent, but Asia Pacific grows faster at 16.6 percent a year. SRI expects the market to pass USD 4.13 billion in 2030.


The policy shift is now concrete on both sides of the Atlantic. In the United States, the Department of Agriculture's SECURE rule exempts many edited plants from biotechnology permitting, while the Food and Drug Administration and the Environmental Protection Agency keep roles for food safety and plant-incorporated protectants. In Europe, the Council and Parliament reached a provisional deal on new genomic techniques in December 2025, Parliament approved the regulation on 17 June 2026, and Regulation (EU) 2026/1388 was published in the Official Journal on 26 June 2026 and entered into force on 16 July 2026. Plants that could also have been obtained by conventional breeding, known as NGT-1 plants, are treated as equivalent to conventional ones, while more complex NGT-2 plants remain under full genetically modified organism rules. For the first time, the world's most cautious large agricultural market has a defined path for edited crops.


Why the Gene-Edited Crops Market Is Entering a New Phase


Three structural forces are converging.


Regulation is moving from prohibition to classification. SRI's research identifies lighter regulation for edited crops as the largest single driver, adding 2.5 percentage points a year to growth, mostly in the short term. The logic is simple: when a small, targeted edit that could have occurred through conventional breeding is no longer treated as a genetically modified organism, the cost and time to bring a trait to market fall sharply. That benefits large breeders such as Corteva Agriscience and Bayer, which use the new rules to widen their pipelines, and it is existential for start-ups such as Pairwise and Cibus, whose business models depend on that pathway. The same regulatory dynamic is visible in crop protection, where biologicals are gaining ground as resistance and rules tighten.


Climate stress has made trait speed a commercial necessity. SRI estimates that climate stress on yields adds 2.1 percentage points to annual growth over the medium term, and climate resilience is the fastest growing trait at 17.3 percent a year. Drought, heat and salinity are arriving faster than conventional breeding cycles of eight to twelve years can respond. Editing can introduce a known tolerance allele into an elite variety in a fraction of that time, which turns breeding from a slow numbers game into a targeted engineering problem.


The cost of the toolkit keeps falling. Falling cost of CRISPR-Cas tools adds 1.8 points, because cheaper editing and sequencing shorten trait development cycles and allow more crops to be tried. Consumer-facing quality traits add a further 1.5 points in the long term, as retailers and food processors look for better nutrition, shelf life and taste. Together the four drivers add 7.9 points to annual growth, while two restraints, uneven regulation across regions and patent licensing complexity, remove 3.0 points.


These forces explain SRI's forecast of a market that nearly quadruples between 2025 and 2035, with growth concentrated in climate and disease traits, in base and prime editing, and in Asia Pacific.


Gene-edited crops market data snapshot: USD 2.10 billion in 2025 to USD 8.13 billion by 2035 at 14.5 percent CAGR, with CRISPR-Cas share, seed company share and EU NGT regulation milestones

Five Lessons From the Companies Moving First


The seed companies, trait developers and public breeders converting gene editing from a laboratory capability into commercial varieties share a recognisable pattern. We have distilled it into five lessons, each followed by a takeaway for a specific leadership function.


Lesson 1: Design Every Trait for the Strictest Regulator You Want to Sell To


The same edited plant can be sold freely in one country and treated as a genetically modified organism in another. SRI's research names uneven regulation across regions as the largest restraint, removing 1.9 points from annual growth. The companies moving first have responded by designing traits that fit the narrowest regulatory definition they need to meet. Under the new European framework, that means edits that stay within NGT-1 criteria, so that a variety developed for the United States can also be registered in Europe without a separate genetically modified organism dossier.


This is a design choice made at the start of a programme, not a compliance task at the end. A small knockout or a single-base change may qualify; an inserted gene from an unrelated species will not. The breeders that map each target trait against the definitions in the United States, the European Union, Japan, Argentina and other key markets before the first edit is made avoid stranded programmes later. Europe holds 15.00 percent of 2025 revenue in SRI's research and grows at 12.4 percent, held back so far by unsettled rules; a design-for-the-strictest-market approach is how companies capture that region as the rules come into effect.


"In gene editing, the regulatory category is decided at the bench. The companies winning are the ones that know which countries they will sell into before they choose which base pair to change."

Takeaway on strategy. Build a regulatory map for every trait programme before research begins, and prioritise edits that qualify as conventional-equivalent in all target markets. Treat Europe's 2026 framework as a market opening, not a footnote, and budget for the registration, labelling and seed-marketing steps that still apply to NGT-1 varieties.


Lesson 2: Climate and Disease Traits Are Where the Value Is Moving


Yield improvement is the largest trait with 28.00 percent of 2025 revenue, worth USD 588.00 million, but it grows at 13.0 percent a year, slower than the market, because yield genes are often complex and hard to change with a single edit. Disease resistance holds 26.00 percent and grows 15.1 percent to USD 2.24 billion; quality and nutrition holds 17.00 percent and grows 16.0 percent to USD 1.58 billion; climate resilience holds 14.00 percent and is the fastest at 17.3 percent, reaching USD 1.46 billion by 2035. Herbicide tolerance, the trait that defined the first generation of biotech crops, holds 15.00 percent and grows only 10.7 percent, the slowest of the five, and SRI expects it to lose share steadily.


The shift reflects what farmers will pay for. A trait that cuts production risk, by surviving a drought or resisting a fungal disease, delivers value in the field every season. It also fits with the move toward lower chemical inputs that is reshaping the wider crop inputs market, from biostimulants and microbials that help crops manage stress to biological crop protection. An edited variety with built-in disease resistance reduces spraying, which matters both for cost and for the regulatory pressure on chemical actives.


Takeaway on research and development. Weight the portfolio toward disease resistance and climate resilience, where SRI's research shows the fastest growth, and toward quality traits with a visible consumer benefit. De-emphasise herbicide tolerance programmes unless they are part of an integrated input offer, and measure each trait by the risk it removes from the farmer's season.


Lesson 3: Precision Editing Is the Next Technology Moat


CRISPR-Cas holds 71.00 percent of 2025 revenue, worth USD 1.49 billion, and grows at 14.4 percent, in line with the market. Base and prime editing holds 12.00 percent, worth USD 252.00 million, and is the fastest technique at 20.6 percent, reaching USD 1.64 billion by 2035. TALEN holds 11.00 percent and zinc finger nucleases 6.00 percent.


The reason precision matters is both technical and regulatory. Base and prime editors change individual letters of DNA without cutting both strands, which allows breeders to recreate a specific beneficial allele found in a wild relative or another variety. That precision makes it easier to show that the result could have arisen through conventional breeding, which is the test that matters under NGT-1 and similar rules. It also widens the set of traits that can be addressed, including subtle changes to nutrition and quality that a simple knockout cannot achieve.


Precision also intersects with intellectual property. SRI's research names patent licensing complexity as a restraint, removing 1.1 points, because overlapping rights on core editing tools raise freedom-to-operate costs, especially for smaller breeders. Corteva Agriscience holds a large licensing position in core CRISPR patents, and the companies moving first have either secured licences early or invested in alternative editing systems.


"The first wave of gene editing was about cutting. The next wave is about writing, and the companies that can make a single precise change, cleanly and with clear freedom to operate, will own the most valuable traits."

Takeaway on technology and intellectual property. Invest in base and prime editing capability and in proprietary or well-licensed editing systems. Audit freedom to operate across every target market before advancing a trait, and treat licensing strategy, whether in-licensing core tools or out-licensing traits, as a revenue and risk lever rather than a legal afterthought.


Lesson 4: Distribution Through Seed Companies Decides Who Gets Paid


Seed companies are the largest end user with 58.00 percent of 2025 revenue, worth USD 1.22 billion, and they grow 14.6 percent a year to USD 4.77 billion in 2035. They hold the germplasm, the breeding programmes and the regulatory teams that bring a trait to market, and they control the route to the farm. Farmers and growers hold 22.00 percent, worth USD 462.00 million, and grow fastest at 15.7 percent as edited varieties reach commercial seed catalogues. Research institutes hold 20.00 percent and grow 12.5 percent through publicly funded programmes in rice, wheat, cassava and banana.


SRI's view is direct: start-ups that can only sell to seed companies should secure at least one large partner early, because distribution is the bottleneck. Pairwise, which has developed edited fruits and vegetables such as a reduced-pit cherry and a less pungent mustard green, licenses its platform to large seed companies. Bayer develops short-stature corn and vegetable traits in-house and through partnerships with editing start-ups. Syngenta, BASF, KWS SAAT and Limagrain each run editing programmes inside established breeding pipelines. The trait is only worth what the germplasm and the channel can carry.


Data is becoming part of the same distribution story. As precision farming turns field data into the basis for input decisions, seed companies that can pair an edited variety with agronomic recommendations will capture more of the value than those selling seed alone.


Takeaway on go-to-market. For trait developers, lock in at least one major seed partner for each priority crop and region before scaling research spend. For seed companies, treat editing start-ups as an external research pipeline and structure licences to secure exclusivity in core crops. For both, package edited varieties with agronomic data and advice to strengthen the farmer relationship.


Lesson 5: Consumer and Retailer Trust Is a Market Access Issue


Regulatory approval opens the door; consumer and retailer acceptance decides how far it opens. SRI's research lists consumer and retailer resistance to genome-edited food, and stricter rules or labelling requirements in key export markets, among the challenges. The European framework includes labelling of NGT seed and plant reproductive material, and debates over consumer choice continue. Exporters must also track how importing countries treat edited commodities, because a variety approved at home can still face barriers abroad.


The companies moving first have chosen their early products carefully. Quality and nutrition traits, such as high-oleic oils and tomatoes with raised gamma-aminobutyric acid, give consumers a visible benefit, which builds acceptance in a way that agronomic traits alone do not. Transparent communication about what an edit does, and how it compares with conventional breeding, is becoming a standard part of product launches.


The capabilities that decide who captures this demand are specific:


  • Trait design that meets the strictest regulatory definition in every target market.

  • A portfolio weighted toward disease resistance, climate resilience and consumer-facing quality traits.

  • Base and prime editing capability with clear freedom to operate.

  • Distribution partnerships with seed companies that own germplasm and farmer relationships.

  • Transparent communication and consumer-benefit products that build acceptance with retailers and the public.


Companies evaluating these competitive dynamics in greater detail can use SRI's Gene-Edited Crops Market analysis to assess technique, crop, trait, end-user and regional segments and the positioning of the leading seed and trait companies.


Five lessons framework for gene-edited crops: design for the strictest regulator, climate and disease traits lead, precision editing is the moat, seed company distribution decides value, consumer trust is market access

Takeaway on regulatory affairs and communication. Track labelling and import rules in every export market alongside domestic approvals. Lead with consumer-benefit products where possible, publish clear explanations of each edit, and engage retailers early so that market access is secured before volume arrives.


Where the Opportunity Is Concentrating


Value is moving toward climate and disease traits, toward precision editing and toward Asia Pacific.


By technique, CRISPR-Cas remains the workhorse with 71.00 percent of 2025 revenue, while base and prime editing grows fastest at 20.6 percent as breeders seek precise, regulation-friendly changes.


By crop, cereals and grains lead with 39.00 percent of 2025 revenue, reflecting the scale of rice, wheat and corn programmes, while fruits and vegetables are a focus for consumer-facing quality traits.


By trait, yield improvement is the largest pool, but climate resilience, quality and nutrition, and disease resistance all grow faster than the market, and herbicide tolerance loses share.


By end user, seed companies hold the market and the route to the farm, farmers and growers are the fastest growing buyers as edited varieties reach seed catalogues, and research institutes anchor public programmes in staple crops.


By geography, North America is the largest market at 36.00 percent on the strength of its exemption-based rules, Asia Pacific holds 34.00 percent and grows fastest at 16.6 percent, Latin America grows 14.8 percent, and Europe, at 15.00 percent and 12.4 percent growth, is the region where the 2026 law could change the trajectory most.


At the Horizon: What to Watch Over the Next Three Years


Europe's first NGT-1 registrations. The pace at which edited varieties are verified as NGT-1 and listed in national catalogues will show whether the new regulation delivers a faster path in practice, and which breeders are ready to use it.


Patent settlements and licensing terms. Disputes and cross-licences over core editing tools will set the cost of freedom to operate, especially for smaller breeders and public institutes.


Climate-resilient staples in Asia Pacific. Commercial releases of drought, heat and salinity tolerant rice and wheat in the fastest growing region will be the clearest test of whether climate traits translate into farmer demand.


"Gene editing has stopped being a question of whether regulators will allow it. It is now a question of which breeders can turn a precise edit into a variety that farmers buy, retailers stock and consumers trust."

The Strategic Revenue Opportunity


For seed companies, the task is to integrate editing into breeding pipelines, design traits for multi-market approval and secure licences to core tools. For trait developers and start-ups, the priority is to partner early with seed companies that own germplasm and distribution. For research institutes, the opportunity lies in climate-resilient staples for regions where public programmes drive adoption. For food companies and retailers, consumer-benefit traits offer differentiated products. For investors, the signal is the regulatory opening in Europe combined with the fastest growth in Asia Pacific.


Market intelligence turns these questions into decisions. Segment-level sizing shows where trait and technique value is concentrating, competitive analysis shows how seed majors and start-ups are positioned, and regional analysis shows where regulatory change will pull demand first. This is the path from market signals to strategic insight to revenue impact.


Takeaway on revenue. Treat the gene-edited crops market as four revenue pools: edited seed sold through established seed channels, trait licences sold to seed companies, editing platforms and tools licensed to breeders, and publicly funded programmes in staple crops. Each needs its own pricing, partnership and regulatory model. Enter where the regulatory path is clear and the trait removes a visible risk from the farmer's season.


The Next Leg: Preparing for the Journey Ahead


The defining shift in gene-edited crops is that regulation has moved from a wall to a gate. That changes the cost of bringing a trait to market, the set of companies that can compete and the crops that are worth editing. The companies moving first are not the ones with the most edits in the laboratory; they are the ones designing for the strictest regulator, prioritising climate and disease traits, mastering precision editing, partnering for distribution and building consumer trust.


The next three years will decide which breeders turn Europe's new framework and Asia Pacific's growth into commercial varieties. Decision-makers should map regulation trait by trait, invest in base and prime editing, secure seed partners and lead with products that show a clear benefit. Companies evaluating growth opportunities in this market can use Strategic Revenue Insights' Gene-Edited Crops Market report to assess market size, competitive dynamics, regional opportunities and strategic growth priorities.


Sources: Strategic Revenue Insights, Gene-Edited Crops Market report (2026); Council of the EU and European Parliament, provisional agreement on new genomic techniques (December 2025); Regulation (EU) 2026/1388, Official Journal of the European Union (June 2026).


Frequently Asked Questions


How big is the gene-edited crops market?


Strategic Revenue Insights values the global gene-edited crops market at USD 2.10 billion in 2025 and forecasts USD 8.13 billion by 2035, a 14.5 percent compound annual growth rate. The market should pass USD 4.13 billion in 2030, and North America holds the largest share at 36.00 percent of 2025 revenue.


What is driving growth in gene-edited crops?


According to Strategic Revenue Insights, lighter regulation for edited crops adds 2.5 percentage points a year to growth, climate stress on yields adds 2.1 points, falling CRISPR-Cas tool costs add 1.8 points and consumer-facing quality traits add 1.5 points. Uneven regulation across regions is the largest restraint, removing 1.9 points.


Which segment of the gene-edited crops market grows fastest?


Base and prime editing is the fastest growing technique at 20.6 percent a year, climate resilience is the fastest trait at 17.3 percent, and farmers and growers are the fastest end user at 15.7 percent, according to Strategic Revenue Insights. Asia Pacific is the fastest growing region at 16.6 percent a year.


How does the EU regulate gene-edited plants?


Regulation (EU) 2026/1388 entered into force on 16 July 2026 after Parliament approved it in June 2026. Plants that could also be obtained by conventional breeding, called NGT-1 plants, are treated as equivalent to conventional plants, while more complex NGT-2 plants remain subject to full genetically modified organism requirements.



About the authors: This article was prepared by the Strategic Revenue Insights research team, which combines market intelligence, competitive analysis and strategic advisory for growth-stage, mid-market and enterprise organisations across the agriculture sector.


Sector analyst: Sandeepa Kulkarni, Research Analyst. Our market estimates combine primary research (interviews, surveys and expert panels) with secondary data (industry reports, databases and public disclosures); read more about how Strategic Revenue Insights works. To discuss this market with our analysts, contact our team.


Comments


Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page